Axitinib is a small molecule commercialized by Clearside BioMedical, with a leading Phase II program in Wet (Neovascular / Exudative) Macular Degeneration. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Axitinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Axitinib is expected to reach an annual total of $46 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Axitinib is under development for the treatment of choroidal neovascularization and wet age-related macular degeneration. The drug candidate is administered in suprachoroidal space through a micro needle. The drug candidate target both VEGF and PDGF. It is being developed based on SCS platform technology.
Clearside BioMedical Overview
Clearside BioMedical (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise of CLS-AX, XIPERE and SCS Microinjector. Clearside’s proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight threatening disease often occurs. The company also offers services such as business development, license agreements and contract manufacturing services. Clearside has partners with various pharmaceutical companies for the commercialization and development of its products across the US, Canada, China, Hong Kong, Macau, Taiwan and South Korea, among others. It markets its products across the US. Clearside is headquartered in Alpharetta, Georgia, the US.
The company reported revenues of (US Dollars) US$1.3 million for the fiscal year ended December 2022 (FY2022), a decrease of 95.5% over FY2021. The operating loss of the company was US$29.6 million in FY2022, compared to an operating profit of US$0.4 million in FY2021. The net loss of the company was US$33 million in FY2022, compared to a net profit of US$0.4 million in FY2021.
For a complete picture of Axitinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.